Lydia Atangcho1, Tejas Navaratna1, Greg M Thurber2. 1. Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA. 2. Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA. Electronic address: gthurber@umich.edu.
Abstract
Stabilized peptide therapeutics have the potential to hit currently undruggable targets, dramatically expanding the druggable genome. However, major obstacles to their development include poor intracellular delivery, rapid degradation, low target affinity, and membrane toxicity. With the emergence of multiple stabilization techniques and screening technologies, the high efficacy of various bioactive peptides has been demonstrated in vitro, albeit with limited success in vivo. We discuss here the chemical and pharmacokinetic barriers to achieving in vivo efficacy, analyze the characteristics of FDA-approved peptide drugs, and propose a developmental tool that considers the molecular properties of stabilized peptides in a comprehensive and quantitative manner to achieve the necessary rates for in vivo delivery to the target, efficacy, and ultimately clinical translation.
Stabilized peptide therapeutics have the potential to hit currently undruggable targets, dramatically expanding the druggable genome. However, major obstacles to their development include poor intracellular delivery, rapid degradation, low target affinity, and membrane toxicity. With the emergence of multiple stabilization techniques aical">nd screening technologies, the high efficacy of various bioactive n class="Chemical">peptides has been demonstrated in vitro, albeit with limited success in vivo. We discuss here the chemical and pharmacokinetic barriers to achieving in vivo efficacy, analyze the characteristics of FDA-approved peptide drugs, and propose a developmental tool that considers the molecular properties of stabilized peptides in a comprehensive and quantitative manner to achieve the necessary rates for in vivo delivery to the target, efficacy, and ultimately clinical translation.
Authors: Mireille Dumoulin; Katja Conrath; Annemie Van Meirhaeghe; Filip Meersman; Karel Heremans; Leon G J Frenken; Serge Muyldermans; Lode Wyns; Andre Matagne Journal: Protein Sci Date: 2002-03 Impact factor: 6.725
Authors: Samuel K Sia; Peter A Carr; Andrea G Cochran; Vladimir N Malashkevich; Peter S Kim Journal: Proc Natl Acad Sci U S A Date: 2002-11-04 Impact factor: 11.205
Authors: Daniel F Veber; Stephen R Johnson; Hung-Yuan Cheng; Brian R Smith; Keith W Ward; Kenneth D Kopple Journal: J Med Chem Date: 2002-06-06 Impact factor: 7.446